Nancy Lurker - Jul 10, 2025 Form 4 Insider Report for EyePoint Pharmaceuticals, Inc. (EYPT)

Role
Director
Signature
/s/ Ron Honig, Attorney-in-Fact
Stock symbol
EYPT
Transactions as of
Jul 10, 2025
Transactions value $
$0
Form type
4
Date filed
7/11/2025, 04:06 PM
Previous filing
Jul 2, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lurker Nancy Director C/O EYEPOINT PHARMACEUTICALS, INC., 480 PLEASANT STREET, WATERTOWN /s/ Ron Honig, Attorney-in-Fact 2025-07-11 0001450485

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EYPT Common Stock Options Exercise $0 +11.1K +5.41% $0.00 217K Jul 10, 2025 Direct
holding EYPT Common Stock 127K Jul 10, 2025 By Family Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EYPT Restricted Stock Units Options Exercise $0 -11.1K -50% $0.00 11.1K Jul 10, 2025 Common Stock 11.1K $0.00 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held in a trust for the benefit of the reporting person's children. The reporting person's spouse is trustee of the Family Trust. The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 The restricted stock units vests in three ratable annual installments beginning July 10, 2024.